For those interested, see below the relevant charts relating to (1) tumor burden; and (2) survival curves for CF33 in a nude mouse model. This is only pre-clinical evidence and should not be treated as evidence for efficacy in humans for obvious reasons. Retrieved from Woo et al (2020).
Figure 4 - Tumour Burden
Figure 5 - Survival Curves
Hope this helps. As always, DYOR!
Ann: Imugene to Present Oncolytic Virus Data at AACR21 Meeting, page-11
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
-0.003(5.08%) |
Mkt cap ! $411.5M | |||
| Open | High | Low | Value | Volume |
| 5.9¢ | 5.9¢ | 5.5¢ | $2.898M | 51.11M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 41 | 4186955 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 337877 | 2 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |